Latest / Psychopharmacology Today / Ep. 6: Ketamine in the Treatment of Mental Health Conditions: A Primer
Transcript
- 0:05On behalf of Alliant's Clinical Psychopharmacology Program, I would like to welcome you to: Ketamine Ketamine in the Treatment of Mental Health Conditions, a Primer.
- 0:15We're going to explore what experience and research show about the effects of ketamine ketamine when delivered within a therapeutic setting for individuals battling depression,
- 0:23suicidal ideation, and other mental health conditions.
- 0:26What does the data say about the use of psychotropic use of ketamine?
- 0:29ketamine?
- 0:29And what's the way to achieve the best outcome with patients?
- 0:33We are going to learn the facts and fiction behind the power of ketamine ketamine in this fascinating webinar.
- 0:39We have Dr.
- 0:40Alex Papp, MD, ABPN, and Dr.
- 0:44Julie Myers, PsyD, MSCP.
- 0:47They work together in private outpatient setting at the Point Loma Clinic here in San Diego.
- 0:52And they teach courses in depression and PTSD in the clinical psychopharmacology program here at Alliant.
- 0:59So I believe we're going to have Dr.
- 1:02Myers start the presentation.
- 1:03Dr.
- 1:04Papp will be taking over at some point.
- 1:07Dr.
- 1:07Myers, thank you for being here.
- 1:09Well, thank you.
- 1:10So it's great to be doing this again.
- 1:12So there are some new data in here and a little more stumbling on our part trying to present that data.
- 1:17Some of the slides are fairly dense, particularly the talk by Dr.
- 1:22Papp.
- 1:23So we're pleased to be here.
- 1:25Dr.
- 1:26Papp is actually going to be starting off.
- 1:27I'm kind of just doing the intro thing.
- 1:29And he's going to be talking about more of the sort of deep science behind it, the chemistry of ketamine and the psychopharmacology, how it works,
- 1:38and why it works and how it really differs from some of the traditional antidepressants and who is really, what are the contraindication indications for using ketamine with
- 1:48people.
- 1:49And then I'm gonna take over in a more...
- 1:52sort of the more practical side of what ketamine treatment looks like in the real world.
- 1:57And kind of remembering that, you know, this is, we have our own way of doing things.
- 2:00We're gonna try to present
- 2:01how other people are doing it in a fair way, but we may have some slants and biases on this, but we'll attempt not to do so.
- 2:08And then, you know, make sure, really present what are best practices in the industry and give you some case examples.
- 2:15So with that, I'm going to go ahead and turn it over to Dr.
- 2:19Papp and we're kind of doing it the old-fashioned way.
- 2:21We just kind of move chairs in the same room.
- 2:24So here's Dr.
- 2:24Papp.
- 2:25Good afternoon everyone.
- 2:26Let's start quickly with the history of ketamine.
- 2:29Ketamine is the offspring of phencyclidine, which is PCP, which was developed in the 1950s for anesthesia in humans.
- 2:38But very quickly it became clear that it has
- 2:41really bad side effects including dissociation and causing psychosis, from which reason it was stopped being used in medicine.
- 2:49But of course there was a reason why it became a drug in the streets that we're still plagued with.
- 2:54So that was in the 1950s.
- 2:56So by the 1960s, it was widely used in surgical settings, both for short anesthesia, for small procedures and induction of full anesthesia.
- 3:07Then of course, as we all know, ketamine also escaped medical practice and by the 1980s, it became a popular
- 3:14rave and dance drug still to this day.
- 3:18I can't imagine how people can dance on ketamine but clearly that's been done.
- 3:22Meanwhile, its medical use continued.
- 3:25There were a few studies, a few observations of people who received ketamine for anesthesia who reported their depression getting better.
- 3:33Eventually, somebody decided to make a very simple study, which was published in 2000 by a person named Berman.
- 3:42This was the outcome of the study.
- 3:44You can see
- 3:45that...
- 3:45this is 72 hours.
- 3:47This is the treatment line.
- 3:49This is the placebo line.
- 3:51I'm not sure what scale this was, but this was the original depression number.
- 3:57And there was a very, very significant drop in depression numbers within 72 hours.
- 4:04This is not something that has ever been seen in psychiatry by any medication.
- 4:08It was so unusual that it took at least five years for the next study to be conducted.
- 4:14But after that, eventually, slowly, it became more and more widespread in academic institutions,
- 4:20drifted out into private practice and by 2020 there were already 500 known ketamine clinics in the US and by now there's over several thousand.
- 4:31So let's see what ketamine actually is.
- 4:33Ketamine is a molecule which comes in two forms, the left form and the right form.
- 4:39These are called racemic mixtures.
- 4:41And you can imagine very much like your hands.
- 4:44So your hands are actually racemic mixtures of the thing called "hand." One side is called S-ketamine, which is the left side, the other side called R-ketamine, which is the right
- 4:52side.
- 4:53The different versions, different mirror images are called the enantiomers.
- 4:57This is a mirror symmetry that is observable in many medications.
- 5:02In fact, most of medications that you take come in a racemic mixture, but many times it doesn't matter which side is active because they're both equally active.
- 5:12There's one medication that most of you have heard about where
- 5:16the racemic differences are significant.
- 5:20And that is with respect to Celexa, which is citalopram, and Lexapro, which is escitalopram.
- 5:26So let's see how it actually occurs in real life.
- 5:29So there is S-Ketamine and there is R-Ketamine, as I said.
- 5:33The S version of ketamine seems to have a higher affinity for the NMDA receptor than the R, which means that it activates it more readily than the R.
- 5:43On the other hand, the R version seems to have a longer lasting anti-depressant effect in animal studies.
- 5:48Because of this known effect, the higher affinity, the drug company that eventually decided to, first decided to market ketamine, decided to go with the S-ketamine.
- 5:58It turns out that maybe R-ketamine would be better long-term or more effective even though needing a little bit more for patients to achieve the effect.
- 6:07R-ketamine is currently under development as an antidepressant.
- 6:10And S-ketamine as we know now has been approved for several years as a form of nasal spray called spravato.
- 6:17The ketamine infusions, injections, and many of the other formulations used in semi-medical settings are all using the original racemic ketamine.
- 6:31As I was told by an attendee of a conference about ketamine
- 6:36in Oxford (this person was from Brazil) and he said that, to his knowledge, Brazil is the only country in the world where actually S-ketamine is the only ketamine available in
- 6:44terms of pharmacological use.
- 6:51Ketamine is metabolized like every medication, or most medications, is metabolized by the enzymes in the liver, the CYP enzymes.
- 6:52Let's see what happens with ketamine in the body.
- 7:00The two major enzymes that metabolize ketamine are 3A4 and the 2B6.
- 7:06The first step is
- 7:08metabolized by 3A4 and the other steps are metabolized by 2B6 and there are other side branches that are metabolized by other enzymes but these are the most important ones.
- 7:20So the first breakdown product is called norketamine.
- 7:23From that, we get hydroxy norketamine, which is an interesting product on its own and usually just simply referred to as HNK.
- 7:31From which we get dehydroxy norketamine, et cetera.
- 7:34So you can see that the ketamine goes through a lot of steps, which results in it breaking down.
- 7:39Now the interesting thing is that most of the breakdown products are themselves psychoactive.
- 7:43The total action of ketamine eventually comes from the combined effect of the original ketamine and all these metabolites, both the S and the R form.
- 7:54This is called an entourage effect.
- 7:56You can see entourage effect in medications like, or agents like, for instance, St.
- 8:01John's wort.
- 8:02It contains dozens of different kind of pharmacologically active chemicals.
- 8:05The combined effect is called an entourage effect.
- 8:07Cannabis contains lots of different chemicals and the total effect is an entourage effect, which also means that because of all this known variation in terms of enzyme activities in
- 8:18people, some people have more of this
- 8:20in their system circulating.
- 8:22So it is hard to say what exactly is the total full effect of the entourage depending on the situation.
- 8:29You can see what happens if you give ketamine intravenously.
- 8:33So this is a slide that describes the effect of the blood levels of ketamine and two of the byproducts, norketamine and hydroxynorketamine.
- 8:43The gray column is the time during which ketamine is administered intravenously; it's usually 40 minutes.
- 8:49You can see that the ketamine goes into the system and continues to go up, up, up, up, up, but then it begins to turn downwards because the metabolism begins to start.
- 9:00So you see that the metabolic parts are increasing and very quickly they take over most of the effect of ketamine and ketamine itself is declining very rapidly.
- 9:11So first, norketamine and eventually hydroxynorketamine are increasing and they
- 9:16take over the effect of the parent compound, ketamine.
- 9:20Like I said, it occurs both for the R and the S versions equally.
- 9:24Now what happens if you give ketamine orally?
- 9:27When you give ketamine orally, most of the medication is metabolized by the liver before it reaches the bloodstream that eventually circulates it to the brain.
- 9:40So most of the ketamine...
- 9:43and this one is a different study, and it did not show hydroxynorketamine.
- 9:49So this would be the norketamine, the concentration of norketamine increases and the ketamine itself barely budges because most of it gets metabolized by the liver before it
- 10:01reaches the general circulation.
- 10:03Hydroxynorketamine would be something like this, going like this and then goes this way.
- 10:08Another thing that I would like you to look at is the length difference.
- 10:12So this is three hours.
- 10:14So this is five hours, 300 minutes.
- 10:16It is represented by this red line.
- 10:18It is the same length
- 10:20here, it is five hours here.
- 10:22So you can see that with IV administration, within five hours, most of the effect is completely gone.
- 10:28In oral administration at five hours, you just having the peak effect of norketamine and then you start having the peak effect of the hydroxynorketamine.
- 10:37So you can see there's a huge difference between administering ketamine IV (and IM is fairly similar to this)
- 10:44versus any other administration that does not bypass the liver.
- 10:48So when you say, I got ketamine...
- 10:51I got ketamine intravenously or I got ketamine sublingually, you got a really very, very different treatment.
- 10:55Let's see what happens as ketamine affects the brain.
- 10:58We're going to look at the cellular effects of ketamine and then we're going to look at the macro cellular effects of ketamine later.
- 11:05This is up here just to give you an idea of the complexity of the process.
- 11:10This is not something I'm going to talk about in any detail except the fact that the main effect of ketamine that we're looking for is an increased glutamate effect in the
- 11:20prefrontal cortex and some other structures, including the hippocampus.
- 11:24This is the main thing that we're trying to achieve, both with ketamine and antidepressants in general.
- 11:29And then it has other effects that eventually feedbacks into the antidepressant effect that you're trying to achieve.
- 11:34You get ketamine, all kinds of things happen, then glutamate activity increases in this particular brain structure than a few others, which then result in an antidepressant
- 11:45effect.
- 11:45Things to understand is ketamine increases glutamate activity in the prefrontal cortex.
- 11:49The key effect of ketamine is an NMD receptor blocking effect.
- 11:55The NMD receptor is a glutamate receptor.
- 11:57So how come you are blocking a glutamate receptor and you're increasing glutamatergic activity in the brain?
- 12:05Well, it is the result of the inhibition of inhibition.
- 12:09So let's see what that means.
- 12:11Here's a little graph.
- 12:12It's a schematic graph of a part of the brain that it would be in prefrontal cortex.
- 12:20So there are so-called NMD neurons that give a certain baseline activity to GABA neurons.
- 12:27And most of you know
- 12:28that GABA activity is inhibitory.
- 12:31So if there are NMDA neurons that are activated by glutamate, there's a normal course of action.
- 12:38That is going to activate to some degree the GABA neuron, but it's an inhibitory neuron.
- 12:43So what happens if an inhibitory neuron is working?
- 12:46It is going to inhibit something.
- 12:48So the downstream effect of glutamate on the NMDA receptors
- 12:52is through increased inhibitory effect because of GABA neuron activity.
- 12:57Now what happens if you block and so on?
- 12:59The other side of this graph is when ketamine blocks the effect of glutamate then this neuron is not giving as much excitation to the GABA neuron in this system.
- 13:09The GABA neuron as an inhibitory neuron becomes less inhibitory,
- 13:12which means that there's going to be a disinhibition.
- 13:16There's a reduction of inhibition in the downstream processes.
- 13:21And that's how blocking the glutamatergic activity on this neuron overall increasing the glutamatergic activity in another part.
- 13:29Now studies show that when you block the NMDR receptor, it removes the excitation on the inhibitory neurons.
- 13:36And here, the general glutamatergic neurotransmitter activity, the AMPA activity, is going to increase.
- 13:44NMDA neurons are very specific, they are occurring in very specific parts of the brain.
- 13:48Ampereceptors are widespread, the general baseline, garden variety glutamate receptors in the brain.
- 13:54So it is not going to be increased everywhere in the brain, this activity, except in the parts of the brain where there is NMDA neurons.
- 14:04The overall effect, as we're gonna see on the next few slides, is an increase in synaptic growth, which can be shown in studies to be correlated with reduction in depression.
- 14:15So when this happens, the activity of the prefrontal cortex increases as a result of glutamate or ketamine, then
- 14:23there is an increased production of these neuroplasticity factors, the BDNF, mTORC1.
- 14:28BDNF is brain-derived neurotrophic factors, and mTORC1, if you want to know, it's mechanistic target of rapamycin complex 1.
- 14:36These are very important large molecules if their activity and number increases in crucial areas of the brain, it results in synaptic growth, even
- 14:46in growth of, creation of new nerve cells sometimes and that is correlated with the antidepressant.
- 14:51So this is the chief cellular effect of ketamine.
- 14:54There's another effect is the opiate receptor blocking effect is a secondary effect.
- 14:58It can be shown that if you block the opiate receptor, then the effect of ketamine is dampened.
- 15:04But this does not...
- 15:05it's not eliminated.
- 15:06And obviously opiate receptor blocking is not enough, not sufficient.
- 15:10So it's neither sufficient nor necessary, it is an added effect that contributes to the effect of ketamine.
- 15:19There are many other effects.
- 15:20There is some effect on reuptake molecules and some serotonin receptors, but they don't seem to be clinically
- 15:29significant.
- 15:30So let's see these cellular effects of ketamine in vivo.
- 15:33There are some really fascinating studies that can be done nowadays on live animals.
- 15:37This is a live animal, a mouse, I think.
- 15:40It's the visualization of a single dendrite.
- 15:43And the advantage of this
- 15:45technique is that you can repeatedly visualize the very same dendrites.
- 15:49So this is really a fascinating thing to me.
- 15:51So this is an animal that is normal, free moving before depression.
- 15:56Then you can model depression in animals in different ways.
- 15:59I put them in water and see when they stop swimming.
- 16:02But there's one way of doing it and this is how they did it: They gave the animal a steroid.
- 16:08The steroid leads to a depression-like state in the animal, so now it's considered to be an animal model of depression.
- 16:15So when you visualize the very same dendrite, you can see a few things.
- 16:20Some of these dendritic spines completely disappear.
- 16:22You can see that the width of the dendrite has shrunken.
- 16:26And you can even see that the other synaptic dendritic spines
- 16:30look shriveled up and degenerated.
- 16:33The dendritic spines are the points where the synapses occur.
- 16:36So every dendritic spine is synapsed to another cell, another dendrite or maybe another axon.
- 16:42But this is a single one that's visualized.
- 16:45When you give ketamine, you can see both that the...
- 16:48the width of the dendrite is recovering, and we'll see that some of the dendritic spines that disappeared are reappearing.
- 16:56And in the studies that they see that the animal which acts depressed in this state no longer acts depressed after ketamine was given.
- 17:04So this is a very poignant representation of the cellular effect of ketamine, which is actually
- 17:10correlated with the antidepressant effect.
- 17:13So basically what ketamine does, it can restore normal physiological function.
- 17:20Okay, so let's look at the effect of ketamine on brain structures.
- 17:24We'll look at cortical structures, which is a prefrontal cortex hippocampus, and we are going to look at subcortical structures, the amygdala and the lateral habenula, which is
- 17:35an interesting little structure that recently became the focus of attention in ketamine studies and also depression studies in general.
- 17:42And then we can look at large-scale networks as well and see how ketamine affects them.
- 17:46So let's see what ketamine does on cortical structures.
- 17:50In the prefrontal cortex, which is the seat of executive function, and it is part of the central executive network, and we'll talk about these networks a little bit later.
- 17:59It leads to glutamate release, this particular mechanism that I described here.
- 18:04It leads to synaptic potentiation, which counteracts the synaptic atrophy seen in depression, promotes the growth of dendritic spines, which enhances synaptic strength.
- 18:14And like I said, it correlates with the resolution of depression.
- 18:18Now the hippocampus, which is critical for memory formation and also spatial navigation, which is just part of the default mode network, it promotes a very similar process called
- 18:29long-term potentiation.
- 18:31It's a process that strengthens connection between neurons and it is the basis
- 18:36of learning and memory.
- 18:37During the ketamine effect, this is what is interesting here, glutamateroid transmission is temporarily disrupted.
- 18:44And that's how people are tripping and seeing all kinds of things and imagining things and the world looks different and they are in a totally different realm.
- 18:52And then it reconstitutes itself, they come back to reality.
- 18:56And sometimes it is described metaphorically as if, let's say you have a jar with a whole bunch of marbles, like compacted together, you know, years of, you know, just pressure
- 19:05and lack of activity, and then you shake it really vigorously and you allow the marbles to settle into a different pattern.
- 19:14That's sort of a metaphor that you can use to conceptualize what happens in the brain, especially in the hippocampus, when new learning can occur, and that is
- 19:26the state of mind when the settling occurs, and of course the settling occurs not in a few seconds, the settling occurs in the course of hours and a couple of days.
- 19:34When people are more...
- 19:35and I think Dr.
- 19:37Meyers mentions that people are more apt to learning from psychotherapy, that's when psychotherapy can be more effective, right after the shaking of the marbles of your brain
- 19:48occurred.
- 19:49And that's subsumed under the concept of neuroplasticity.
- 19:53Now let's look at subcortical structures.
- 19:56The amygdala is a very, very important part of the brain.
- 19:58Now it is central to emotional processing and of the fear response, it's overly active in PTSD for instance.
- 20:06It shows really significant sexual dimorphism.
- 20:11It is smaller in women than in men.
- 20:16And it probably has a lot to do with
- 20:17for instance, women's higher sensitivity to developing PTSD.
- 20:21And it's part of the salience network.
- 20:23Again, I'm going to talk on the salience network in a few slides down.
- 20:26In PTSD, this is where it's most relevant, there's a hyperactivity of the amygdala, which leads to
- 20:34behaviors like increased startle response and hypervigilance.
- 20:37Ketamine reduces the hyperactivity that is seen in PTSD, and that leads to the improvement in hypervigilance and startle response.
- 20:45Sometimes we see it in really dramatic terms.
- 20:49Not directly on the amygdala, but it has effect on the amygdala from the prefrontal cortex, which is supposed to keep the amygdala under control via an inhibitory effect.
- 21:00PTSD, because it increases the activity, restores the activity of the prefrontal cortex, it restores
- 21:07the ability of the frontal cortex to control the amygdala, which is another way it reduces or improves the effect of PTSD.
- 21:18So it both directly reduces the activity and also increases the inhibitory control by the prefrontal cortex over the amygdala because of improved activity or performance by the
- 21:30prefrontal cortex.
- 21:31Now let's look at the other subcortical structure, which is called the lateral habenula.
- 21:36It is a tiny, tiny, tiny little sliver on two sides of the brain.
- 21:40You can imagine it's like two shells, very small, two millimeter wide and maybe three, four millimeter long thing that I think it surrounds one of the channels in the brain.
- 21:54It's not part of these major networks, it is part of the limbic system and it is considered to be part of the reward and aversion network.
- 22:01It is part of the brain that is activated by failure or punishment and it's also activated by pain and stress.
- 22:07It's sometimes called the anti-reward center.
- 22:09Recently in the past five, six years it was shown that the activity of the habenula increases in chronic depression.
- 22:16So it is active as if the person were under punishment when it is not, when he or she is not.
- 22:22So it's a chronically activated part of the brain that makes the person act as if there were pain and stress and failure and punishment, which is probably one of reasons why
- 22:31these are cardinal symptoms of depression per se.
- 22:33Now, the activity of this chronically
- 22:36over-activated lateral habenula is called the "burst firing." In electrical recordings, it looks like this.
- 22:43What ketamine does, it simply eliminates the burst firing.
- 22:47The clinical response occurs immediately; within a few milliseconds.
- 22:49It just stops happening.
- 22:51Obviously, the antidepressant response doesn't occur within a few milliseconds.
- 22:55It takes a good minimum of few hours and up to 24, 48 hours.
- 23:01But it seems to be that something that's the very, very first step that eventually leads to all the other steps,
- 23:06the NMD receptor blockage and the inhibition on inhibition, et cetera.
- 23:11So very interesting stuff.
- 23:12I think we're going to hear more about that.
- 23:14Actually, we were last time at a ketamine conference and somebody came up with an idea to somehow try to get ketamine just to the lateral habenula, nowhere else, and see if it can
- 23:24reduce the overall ketamine effect on the body and just deliver ketamine to the lateral habenula with different kind of interesting means.
- 23:31So, people tried to do something else.
- 23:33Really cool stuff with this.
- 23:34So let's look at the network theory of depression.
- 23:37So let's first look at networks.
- 23:38The networks, as we understand them, in the past 15, 20 years, are not the original networks which were atomically based.
- 23:47You saw center here and then fibers were going this way and fibers going that way and then became like a network.
- 23:53These are parts of the brain that tend to activate together and they are not necessarily like...
- 23:59macroscopically and anatomically, easy to see to be connected.
- 24:03But you can see them being connected on functional studies like functional MRI, PET scan studies, tensor imaging studies, et cetera.
- 24:10Now four or five or maybe now six or seven of these networks have identified the three major ones that are relevant to depression and psychiatry in general.
- 24:21The central executive network, the salience network, and the default mode network.
- 24:26The central executive network is easy; basically it's the network that is
- 24:33involved in sustained attention, complex problem-solving, working memory.
- 24:37The salience network is part of the brain that is involved in detecting and filtering stimuli that only the salience stimuli reach the brain.
- 24:45You know, cat meowing is not going to be noticed; the car going towards you and speeding up, that's going to be noticed by it.
- 24:55It is going to reach through the relevant functional network.
- 24:57Car speeds behind you, towards you, then that salience network is going to make the part of the brain active that's going to make you jump away.
- 25:05Throughout the interconnectedness, the salience network contributes to a variety of functions like communication, social behavior, and self-awareness through the integration
- 25:18of sensory and motor cognitive activities.
- 25:21The default mode network is an interesting part of the brain, which is active when you are not active.
- 25:26When you as a person are not really active, you're not looking, you're not scanning, you're not thinking, you're not trying to solve a complex mathematical equation.
- 25:35It is active when you are at wakeful rest.
- 25:38It occurs when you're doing daydreaming, wondering, but also when you're thinking about others, thinking about yourself.
- 25:44You're recalling the past, planning for a future.
- 25:47So these are very self-focused, self-absorbed activities.
- 25:52The more active the default mode network, the less active the other networks are, and vice versa.
- 25:58In depression, there's an intrinsic hyper-connectivity in the network itself.
- 26:04There's an increased strength of connection between
- 26:07the parts of the default mode network, which you can see that there's a lot of different important structures: the cingulate cortex, the medial prefrontal cortex, angular gyrus,
- 26:15hippocampus, et cetera.
- 26:17So the activity of the default mode network is interestingly chronically increased.
- 26:21That also
- 26:21translates into an increased activity, an increased strength of connection between the default mode network and the salience network, which means that, as I said, the more
- 26:30active this network is, the less active these networks are.
- 26:33So there's a decreased activity in the salience network, also a decreased activity in the central executive network in depression.
- 26:40The result of these decreased functions
- 26:43is that there's going to be poor working memory.
- 26:46There's going to be poor...
- 26:47for instance, as I said before, this poor inhibition of the amygdala, for instance, because the central executive frontal cortex is not active enough.
- 26:56There's going to be poor motivation.
- 26:58These are all symptoms of depression.
- 26:59And due to the increased strength of this connection here,
- 27:03that's going to be increasing rumination because the person is repeatedly inward-focused, even if that's able to be more advantageous to focus on something in the outside world.
- 27:15Poor autobiographical memory, which would represent itself in difficulty recalling positive events from the past, basically like in the past it used to be called
- 27:26state-dependent learning.
- 27:27So this is the state of the networks in depression.
- 27:30There's frontal hyperactivation, there's weak salience detection, and there is a default mode network hyperconnectivity within the network itself.
- 27:38What ketamine does, it reduces, i.e.
- 27:41normalizes, the hyperconnectivity within the default mode network in depressed patients.
- 27:45So it reduces the strength of connectivity.
- 27:47This will not be seen in healthy individuals.
- 27:51So healthy individuals whose connectivity is what it's supposed to be is not going to be decreased by ketamine in the long term.
- 27:57I mean, when you're tripping, everything is different.
- 28:00But it is going to
- 28:02normalize after repeated ketamine treatment, this hyperconnectivity within the default mode network.
- 28:08With that occurring, there's going to be less strength of connection with this to the salience network, which is going to recover from the oppression exerted by the default
- 28:18mode network.
- 28:19So the balance between introspective and externally focused activities are going to be restored.
- 28:25It increases the activity of the central executive network, which of course is going to be the factor that is going to lead to the improvement in the activities of daily living,
- 28:34working memory, concentration, et cetera.
- 28:37Now these things, these effects occur...
- 28:41can be noticeable after a single treatment.
- 28:43A single treatment has a very limited effect.
- 28:46When you give a single treatment, you can see that there's a very quick improvement.
- 28:50This is the MADRS scores.
- 28:51This is one of the depression rating scales that's used mostly in research.
- 28:54So there's a quick reduction in MADRS scores.
- 28:57Again, you would never ever see anything like this with a traditional antidepressant.
- 29:01And then by day seven, it shows a clear...
- 29:04going back to the depressive baseline.
- 29:07This is the study from 2000, the Berman study, I just repeated it here to see that this is very similar to that study.
- 29:15You can recreate this study over and over again.
- 29:18But if you give repeated infusions or injections, any kind of treatment, then this recovery of depression, going back to depression does not happen.
- 29:28So just continued improvement of depression scores is going to be seen.
- 29:33It is not a evidence-based piece of data that you have to give six initial treatments.
- 29:39That's just how it developed in clinical practice.
- 29:42Within six clinical treatments, you get a long enough, enduring enough reduction in depression scores.
- 29:50Now that takes us to the comparison of traditional antidepressants versus the new antidepressants.
- 29:56When you give traditional antidepressants, the SSRIs, tricyclics, et cetera, the main effect of these medications is to give a kick to the serotonin norepinephrine and dopamine
- 30:06system.
- 30:07That the kick occurs, whether it's a reuptake inhibition or something else, it can be seen within hours.
- 30:12And studies show that the receptor is active within a few minutes and then the downstream activity begins to occur within a few hours in the second, third messenger systems.
- 30:22But it's clear that the antidepressant effect does not occur in a couple of hours.
- 30:27It takes three to eight weeks for the next
- 30:30stage to sort of churn through the brain.
- 30:32And these are the steps that lead to BDNA and mTORC gene expression.
- 30:38And this has to do with things that occur in the nucleus and DNA and messenger RNA and other kind of things.
- 30:45And those have to be transported down in the dendrites to the end of the axon, et cetera.
- 30:51So it's a very, long process.
- 30:52A lot of things can go wrong.
- 30:54But eventually, the exact same thing happens with traditional antidepressants, your Prozacs and Lexapros.
- 31:00Eventually, you get an increase in BDNF levels.
- 31:04You see an increase in synaptic proteins.
- 31:06You get an increase in number of neurons and dendritic sprouts.
- 31:09But again, the advantage of ketamine, and again, I just put this little
- 31:12graph here to remind you this is where it happens.
- 31:15It occurs at this point of the process, it bypasses all these long and complicated processes that lead to this point that are the
- 31:24features of oral antidepressants.
- 31:26So a lot of advantages besides the speed, also the fact that there is no constant side effects, the weight gain, sexual side effects, there's no daily medication taken, there's
- 31:36no daily medication side effects.
- 31:38Okay, so let's leave the science behind and let's look at the...
- 31:42just the psychiatric science, so to say, from basic science to medical or psychiatric science.
- 31:48What are the indications of ketamine treatment that are primary and secondary?
- 31:51The primary is definitely depression, non-psychotic depression, some will frown upon giving it to psychotic depression,
- 31:57but it's mostly theoretical, but probably, again, there's no studies showing it in any effect or any, there's no data in psychotic depression, so we're just not doing it.
- 32:07But depression, any form of depression, including what used to be called treatment-resistant depression, bipolar depression,
- 32:13even dysthymic depression or any kind of depression, ketamine is going to be effective.
- 32:18The next very important indication is suicidal ideation with depression, without depression, with a psychiatric indication disease present or without.
- 32:28Suicidal ideation is one of the most
- 32:30dramatic improvements that you can achieve when you give ketamine to patients.
- 32:35In fact, there many patients whose depression improved spectacularly, but the suicidal ideation was completely gone.
- 32:40And that's the main reason why they continue to get the ketamine treatment.
- 32:44And then we have PTSD, which is a third major indication.
- 32:47We can have anxiety disorders, OCD, eating disorders, and substance abuse disorders, with the caveat that ketamine itself is an abusable substance.
- 32:55So you have to be careful how to administer it to patients.
- 32:59Alcohol use disorder seems to be responding well to ketamine treatment.
- 33:04These are the side effects: You can have elevated blood pressure and heart rate.
- 33:08These are almost never serious.
- 33:10Some patients may require anti-hypertension pre-medication, nausea and/or vertigo.
- 33:15That occurs a little bit less frequently, but may require anti-nausea medications.
- 33:20Vomiting is very rare, mostly when people come in with a full stomach, which they should never do.
- 33:25Anxiety can occur during the trip
- 33:28because of the subjected experience.
- 33:30I used to give patients benzos, but now I just talk to them, talk them down.
- 33:35Officially, the psychedelic effect is considered to be a side effect that most patients actually like.
- 33:40In the afternoon, evening, the ketamine wears off, you can have nausea appearing, then you can have light-headedness and some headaches.
- 33:46And for the next few days, some patients
- 33:49report some difficulty falling asleep but then it goes away.
- 33:53There is something called an emergence reaction that occurs in an anesthesia setting when patients are getting much higher dosages of ketamine as they're coming out of anesthesia.
- 34:03It's confusion, agitation, vivid imagery; in psychiatry we don't give high enough dosages that that should be a problem.
- 34:10Long-term side effects, we just don't know, unfortunately, because there is no long-term studies.
- 34:15So long-term studies are done with drug companies and there are no drug companies that would do long-term studies with IV ketamine because there is frankly no money in it for
- 34:23them.
- 34:23So we just don't know.
- 34:25There is an unknown potential of triggering addiction, likely very low, but you have to be aware of the possibility.
- 34:30There's some concerns about liver function.
- 34:33And there is some concern about urinary cystitis.
- 34:36Among heavy ketamine users, I think it's called destructive cystitis or something really horrible that destroys the bladder of these patients completely.
- 34:47It never happens in the clinical settings because we just don't give enough and frequently enough.
- 34:53Basically these patients have ketamine in their system 24/7.
- 34:56We also order liver function tests and urine analysis a few times a year just to make sure that we're not missing something.
- 35:02There are some medications that interact with ketamine and these are the medications that block the two enzymes: the A34 and the 2B6 and same with the enzymes that might induce
- 35:12those medications.
- 35:13So you try to avoid them.
- 35:16And there's pharmacodynamic interactions which means that they just interact with the effect
- 35:20of ketamine in the brain.
- 35:22Benzos and opiates can extend the sedate effect and they can also reduce the antidepressant of ketamine.
- 35:29Other NND receptors, especially lamotrigine, compete for the receptors and that's how they interfere with the effect.
- 35:35People who are on lamotrigine, which occurs quite frequently with depression, need to skip the lamotrigine on the day of ketamine administration.
- 35:43Other contraindications, very few.
- 35:45Unstable heart disease, unstable epilepsy, psychosis, glaucoma, severe liver disease, substance abuse, pregnancy, because animal studies show that NMD receptor development is
- 35:58affected.
- 35:59Children, we just don't have data and therefore not recommended.
- 36:01So summary: The benefits are observed within hours, can be extended if repeated administration.
- 36:08The adverse effects are usually mild.
- 36:10Much is known about biological effects as I described, but we don't really know how it affects, how it transforms into the antidepressant effect.
- 36:17And the main reason why we're doing it is depression, suicidal ideation, and PTSD.
- 36:22And with that I will hand it over to Dr.
- 36:25Myers.
- 36:25Okay, so lot of information and we're gonna...
- 36:30be using some of that information to understand the more practical effects.
- 36:34So it's not necessarily what you think.
- 36:37So people have all sorts of ideas about it.
- 36:40It's done differently by different people.
- 36:42People experience it differently.
- 36:44So let's see what some of the real facts are.
- 36:47Again, we have our own biases about how we do it
- 36:50but let's see what other things are important.
- 36:53One thing to think about is the route of administration.
- 36:56So they're basically for the IV, the IM, the intranasal and the oral.
- 37:01And part of the reason one of these is chosen is first with the clinician, what the clinician feels comfortable with, but also what the patient chooses.
- 37:10So it sort of started with the IV use of ketamine.
- 37:14And that's basically because it was started by anesthesiologists in academic centers and hospitals.
- 37:19And so there's quite a bit of data on it.
- 37:22And that uses the racemic mix, both the right and the left hand side.
- 37:27And then the IM is also using the racemic mix.
- 37:31And it has a similar efficacy to the IV.
- 37:34Along came the intranasal, spravato.
- 37:38It's only the S-ketamine that is used.
- 37:40It's FDA-approved.
- 37:42It's generally considerably less efficacious than IV.
- 37:46And there's also a compounded racemic mix that again is used off-label.
- 37:54It's not FDA-approved.
- 37:56And finally, the sublingual oral is the racemic mix.
- 38:00You might've heard these "troches."
- 38:02One of the issues with the oral is that it's generally unregulated, sort of wild west out there, variable concentrations in the oral mix and limited data and it's often
- 38:15questionably legal.
- 38:16So there was one physician, for example, who got himself licensed in all 50 states and was just sending it out and making a lot of money.
- 38:24There's also the extended release formulation in phase two clinical trials.
- 38:29The provider is going to decide what they're comfortable with, but there may be some good arguments for use of any one.
- 38:39For example, S-ketamine, even though it may be considered to be less efficacious and it's a little messier,
- 38:46tends to just sort of drip out their nose and things like that, but it's covered by insurance.
- 38:50So for some people, this is a necessary thing to have the insurance cover it.
- 38:53It has some standardized protocols that go along with it, more legal protection really, because it's FDA-approved.
- 39:00And there's some evidence that it's a little bit better for the maintenance phase of ketamine.
- 39:07And then the ketamine itself has basically more rapid, robust response and offers more flexible dosing.
- 39:13So the IV or the intramuscular, and there's a lot more clinical experience with it.
- 39:17We do not recommend in our practice the oral ketamine simply because of the, again, this sort of unregulated market that happens with it.
- 39:27And plus more likely to be abused.
- 39:31We heard of one patient who's like, it was just being delivered on his doorstep.
- 39:35And so again, the potential for abuse is a little bit higher.
- 39:39So in choosing what route of administration you're going to use, you also want to think about the bioavailability of the drug.
- 39:46And Dr.
- 39:47Papp sort of presented the different metabolites that happen.
- 39:52With the oral ketamine, for example, S-ketamine, there are going to be more metabolites that are having more effect because the ketamine is subject to first pass metabolism by
- 40:04the liver.
- 40:04And so not as much gets to the brain.
- 40:07So this lower bioavailability of the oral medication means that the metabolites are going to take a stronger role in the effect.
- 40:16The IV and IM reaches the brain without encountering this first pass, the metabolism by the liver.
- 40:22Oral viability is only about 20 to 30%.
- 40:27And even though you saw in the diagram that the effect of the oral ketamine with the metabolites lasted longer than the five hours that is for the IV ketamine,
- 40:38does not mean necessarily that it is having a better effect or more effect just because it's lasting longer, because we're really talking about the downstream effects of the
- 40:49ketamine, which is the most important part of it.
- 40:53So that patient is actually experiencing the more psychoactive parts of the oral ketamine for much longer, which makes it a little more...
- 41:02I would say dangerous in that they are affected by this psychoactively rather than doing exactly what you want it to.
- 41:09So just because it's longer doesn't necessarily mean that it's better in that sense.
- 41:14And then the other thing thinking about the choice would be the strength at the peak effect.
- 41:19So the IM actually has a stronger peak effect to it than the IV, which is stronger than the intranasal and stronger to the oral.
- 41:27And the stronger peak effect means that there's going to be less engagement with the outside world.
- 41:34So for example, if ketamine-assisted therapy is important in the process, there's going to be less ability to communicate with the IM.
- 41:42So what's the right way to give ketamine when you're adding psychotherapy to it?
- 41:49There is no one way that it works.
- 41:51They all basically are taking advantage of the ability of the brain to rewire things, to create more neuronal connections.
- 41:57So you can do it with psychotherapy, no psychotherapy, after, before.
- 42:02We're gonna look at each one.
- 42:05In our practice, we have done all of these.
- 42:07And we've sort of honed it down to the way that seems to work best for both us in the practice and for the patients that we treat.
- 42:16And I would say if there's no therapy at all, we wanna really think about having support for the patient in some other way.
- 42:23So you can just give the ketamine and the drug is still gonna work.
- 42:27There are ketamine clinics that treat many people all at the same time without any support at all.
- 42:33We don't do that way.
- 42:34There's...
- 42:35even if there isn't therapy going along at the time of administration,
- 42:39Dr.
- 42:39Papp is always with the patient the full first time and then only is with that patient during the rest of the treatment.
- 42:48He doesn't have multiple people at the same time.
- 42:50But some people do in ketamine clinics.
- 42:52We don't have a ketamine clinic.
- 42:55We have full psychiatric and psychological services.
- 42:58And so along with that, it's just part of our practice, the ketamine.
- 43:03So you can also have therapy timed to the ketamine administration, especially within the first 24 hours.
- 43:11So because the brain is the most neuroplastic at that time, 24 to 48 hours seem to be the time where it sort of wears off a little bit.
- 43:20There's evidence for timing CBT or other types of therapy to integrate the material for the patient within that 24 to 48 hours is very helpful.
- 43:31A really fascinating study coming out with exposure therapy.
- 43:34We heard at the last ketamine conference in London about doing written exposure therapy with it as successful.
- 43:41So we're kind of waiting on that paper to be published.
- 43:43You can also have therapy at the time of the ketamine administration.
- 43:47Again, that's called ketamine-assisted therapy or it's got some other names to it, but there are many, many approaches to this.
- 43:55And again, less viable with something like IM just because the peak effect, people are really just sort of out of it too much for the whole part of it, but you can still do the
- 44:05Ketamine-assisted therapy with the IM.
- 44:07There are all sorts of training groups that charge a lot of money to learn ketamine-assisted therapy, really the truth is there is no one right way to do it.
- 44:17Psychodynamic, internal family systems, inter-directed supportive therapy, they're all basically doing the primary thing, and the primary thing is to make the patient feel
- 44:27comfortable and safe in the session.
- 44:30So these faster routes of administration could be too much for a lot of interaction.
- 44:36But the higher dose, the more psychedelic experience.
- 44:39So finding that right sort of dose for the patient.
- 44:43Some people hate the psychedelic experience.
- 44:46Some people want the psychedelic experience; it's going to be important.
- 44:49If they really are scared to death, the psychedelic experience, you take it very slowly in terms of the approach of that.
- 44:56So again, many ways to structure the ketamine process, some are good, some are not so good.
- 45:01Just mailing out ketamine to people in the mail is not particularly a good practice.
- 45:07Looking at sort of the different phases of the good practice.
- 45:11In general, these four phases are intake, then before each ketamine administration, their experience itself, and then the integration of the material.
- 45:19And I'm later going to be presenting sort of what we do in our practice for that to maintain the good practice part of things.
- 45:26So the first
- 45:27phase is really intake with providers.
- 45:29And, you know, you don't want to really bring people into your practice for ketamine if they're not appropriate.
- 45:34So Dr.
- 45:35Papp always starts with a full psychiatric interview, which you know is a couple hours.
- 45:40If the main goal is to have ketamine then you need to screen before they even get in.
- 45:47A form is sent out to the patient so they can
- 45:49determine if they're really appropriate for ketamine or not.
- 45:52And Dr.
- 45:52Papp discusses it with them or I discuss with them.
- 45:55So we wanna have that sort of in the intake with the provider.
- 45:58If they are doing ketamine-assisted therapy or I'm gonna be part of it, then do you have an intake with both of us?
- 46:05Some patients choose to have me involved.
- 46:08Some people do not have me involved.
- 46:09Some people have their own therapist involved.
- 46:11There's a wide variety of ways to do this.
- 46:14The first session is really going to be, is the patient appropriate for ketamine?
- 46:19Are there any contraindications?
- 46:21And you want to get baseline assessments.
- 46:22You want to use a PHQ-9 or the BEC, and you'd be surprised how few providers actually do any measurement.
- 46:31I mean, does this patient really have depression, for example?
- 46:34And is the treatment working?
- 46:36They're not taking any sort of measures on that.
- 46:39And then you want to kind of give them an idea of what the ketamine process is going to be like.
- 46:43So in general, the minimum of six sessions scheduled in three weeks.
- 46:48So, if they've got a really busy work week for three weeks, that's not the time to do it.
- 46:52You want to find a time that they can really devote themselves to the treatment and you give them cautions about their medications and things like that at the initial session.
- 47:02Many providers say you have to pay for the six sessions upfront, all in one package.
- 47:09We do not do that.
- 47:10It's just you bring them into the practice.
- 47:13Are they appropriate for ketamine?
- 47:15And if they do a ketamine session and they hate it, why would you make them come back or lose the money?
- 47:19The data says that these six sessions is really where you start to see it.
- 47:23So you try to encourage them
- 47:24to keep with the six sessions and plan for it upfront.
- 47:28So that phase one, where we do this guidelines and planning and I'll show you the documents that we use for that so they can get a really better idea about how they can
- 47:37make the most of the ketamine experience.
- 47:40Because there are things that are helpful and things that are not so helpful.
- 47:44Again, with providers, we generally encourage...
- 47:47look at the patient rather than just the narrow depression piece of it or the PTSD part of it.
- 47:53What is the whole psychiatric look of the patient?
- 47:56Phase two is before each ketamine administration, the patient comes in.
- 48:00If you're doing an IV or IM, you need to know the weight of the patient.
- 48:04Of course, if it's just within the six weeks, there's not going to be a great variety of weight.
- 48:10But if they're coming in more irregularly, you would want to weigh them each time because dose is weight-dependent.
- 48:15And then you want to get their blood pressure, heart rate, temperature and other medical cautions.
- 48:20Did they drink a lot last night?
- 48:22Did they forget and they took their medications?
- 48:26And then sometimes we've had to send people home because their blood pressure is just too high.
- 48:30So they need to get it down before they can come in.
- 48:34And clearly if they're ill, you don't want to put them through this process.
- 48:37And then there's certain medications that are given to pre-medicate.
- 48:40For example, propranolol, if there's a fast heart rate.
- 48:44And some other things, ones to sort of deal with the nausea that the patient may have.
- 48:49Some of those might be given a...
- 48:51prescription before the patient comes in, sometimes they're given in the office.
- 48:55And then make sure that they've skipped things that they should not be taking when they're having the ketamine.
- 49:00And then each session, we do at least the POMS, profile of mood state, or you can use any other measure.
- 49:08Again, most clinicians do not do that, but it's to see like, well, what's the patient coming in with?
- 49:14And then what is it after the session?
- 49:17Some people like to have intent or goal of the session, but not everybody does.
- 49:22It's not important.
- 49:23It's more just having an open sort of approach to the ketamine is generally what we advise.
- 49:30And then you're going to review, of course, the transportation and plan after session because they cannot drive home.
- 49:37We know a patient who actually just was still in sort of a
- 49:42dream state was just let out the front door and wandering the streets and got lost.
- 49:47So you want to know what the plan is for them afterwards.
- 49:50So there's a two hour block set aside for each uh patient.
- 49:54The first 15, 25 minutes is going to be prep and then about 40, 70 minutes of tripping.
- 50:00ah And then 15 to 25 minutes debriefing.
- 50:04This is just sort of a general length of time that happens.
- 50:07So that's the first two phases.
- 50:09Part of the whole picture is going to be the set and the setting, words that you may hear quite often.
- 50:18What are they coming in?
- 50:19What's their state of mind, their mood, attitudes and concerns, things like that.
- 50:20So the set is basically the mindset of the patient.
- 50:23Are they in a sort of an agitated state when they come in?
- 50:27And then the setting is the physical environment.
- 50:28So ketamine was originally given in more of this sort of surgical-like setting.
- 50:33But these have evolved.
- 50:41You just want it to have comfortable, inviting, and safe, warm for the patient, what they'd like, what would make them feel comfortable.
- 50:42And it's also making the patient feel comfortable and safe and calm is actually very, when you consider what happens with the lateral habenula and the fact that we know that
- 50:53stress...
- 50:54it's actually stress that dislodges the ketamine from the lateral habenula.
- 50:58It's really vitally important to have the patient be calm during the session so that it doesn't dislodge from the lateral habenula.
- 51:06And the third phase is the trip.
- 51:09So the first onset is some altered perception.
- 51:11So this is with the IM I can speak to.
- 51:15I have not worked with the IV.
- 51:17But the onset of the altered perception is about two to four minutes after the injection.
- 51:22And then this peak effect is going to be about 10 to 25 minutes.
- 51:26And they are just sort of out of it for that time.
- 51:29You want to monitor their blood pressure, heart rate, O2 saturation, just their general state.
- 51:35So we have pretty sophisticated monitors where, and we're watching them all the time, while the patient, Dr.
- 51:41Papp is monitoring all the vital signs and has a camera on the patient if nobody's in there with them to make sure there's not an agitated state that happens.
- 51:52So you've got it all sort of set up for the monitoring.
- 51:55And then you administer the ketamine.
- 51:56And really the role of the provider, again, no matter what your theoretical orientation would be to, let the patient control the level of intervention they want.
- 52:06Some people want to talk.
- 52:07Some people don't want to talk.
- 52:09Empathetic listening is really what we all do as therapists anyway.
- 52:13If you're a therapist of any kind, you all know how to do that.
- 52:17And make them feel safe and contained and encourage curiosity and a sense of awe.
- 52:22So it doesn't have to have some big intent like I'm gonna go resolve my conflict with my mother.
- 52:28Just, you know, what happens?
- 52:29Just be there and experience what's happening.
- 52:32And then when I'm in with the patient, if I'm doing ketamine-assisted therapy, I record the dialogue and the behavior so that I can then discuss that with the patient later.
- 52:41And then the fourth phase is integration of the material.
- 52:45So the first integration is right after the experience, the experiential phase.
- 52:51And so they're going to encourage them to connect with the material, you know, about what they experienced, how are they feeling about it.
- 52:57There's actually then measures that are taken again.
- 53:01So the POMS is filled out again, at least in our office.
- 53:05They often record about what their experience was like.
- 53:08And you want to make sure that they're medically sound before they leave the office.
- 53:13So the medically sound is going to be, you know, they have to be oriented.
- 53:16They can't be sent out when they're still in a state of disorientation.
- 53:20And make sure they have a safe ride home and remind them no driving for six hours or heavy machinery, any of sort of thing.
- 53:28They leave the office, encourage them to recreate the experience.
- 53:32Go home, sit in an easy chair, play the same sort of music that you listened to in session.
- 53:37And hopefully have some follow-up therapy within the first 20 to 48 hours.
- 53:42But the primary thing, and I put it there, is that avoid stress.
- 53:46So the idea that the ketamine is basically blocking that anti-reward center in the lateral habenula is super important.
- 53:55If you go get in the car, someone's driving home and you get in your car with your spouse and you start arguing, you've already started the process of dislodging the ketamine from
- 54:07the lateral habenula So it's amazing.
- 54:09People just do the ketamine session, then they go right back into their same pattern of arguments or stress.
- 54:16So that's something that we have really stressed in the last
- 54:20couple years because of the new information that came out about it.
- 54:23What are the other elements of good practice, right?
- 54:26So I mean, anytime you give any sort of medication, any kind of therapy, you want to follow good practice because you get better results from it.
- 54:33So people do it differently.
- 54:35Again, some people don't do it at all or do bad practice.
- 54:40But what we have developed over the course of
- 54:43seven years this has been going on.
- 54:46It's just kind of like honed how we do it.
- 54:48What we've added in the last couple of years was this planning session that we do with patients.
- 54:54Not everybody is willing to do it.
- 54:56You tell the patient you're gonna have better outcome if you do this sort of thing, but in general, most patients will do it.
- 55:01I go over really what the ketamine treatment is gonna look like, at least how we do it.
- 55:06What do we know about ketamine treatment?
- 55:09How are you gonna get the most out of it?
- 55:11Sort of explaining some of the terms of it.
- 55:14And then
- 55:14going over them again about the sort of timing of the ketamine treatment that, you know, they really didn't tell the truth that they don't have stressors coming up and they're
- 55:24remodeling their kitchen.
- 55:25They're going to be under severe stress during this.
- 55:27Well, you know, maybe you want to rebook your sessions for a better time.
- 55:32And then the other part, go in great detail with them that the days before the ketamine treatment, what are they going to do?
- 55:40So they gotta minimize their drugs and alcohol.
- 55:42And if they're using alcohol, we have to figure out a plan how they can reduce for those days.
- 55:47Because you're not gonna tell somebody who's drinking suddenly to stop, because that can be life-threatening in itself, but make sure that they're not drinking before the session.
- 55:57Arranging for a (in bold) conflict-free ride.
- 56:01And arranging for their psychotherapy with either somebody outside of our practice that's going to help coordinate it with them or with me.
- 56:09What are they going to do the day of treatment in terms of reducing the stress that they have during that day?
- 56:14We talk about what are the things that they're going to bring to treatment.
- 56:17Some people like bringing their own stuff, right?
- 56:19In the first session, maybe not.
- 56:21But after that, do they like to...
- 56:23have a playlist, which we encourage.
- 56:25It's something that they can listen to before the session.
- 56:28They can listen during the session.
- 56:29They can listen to it afterwards.
- 56:31And it helps sort of recreate the experience.
- 56:33And then they can bring other things with them to session, like a blanket or pillow, things like that.
- 56:37We always provide them, but some people like to bring their own.
- 56:41And then again, if they want to set an intent, you try to make it more general, a sense of awe and peace and things like that.
- 56:48And then the next part is, you know, before your appointment, what are the guidelines about what are you going to do before?
- 56:56You're not going to have a big breakfast if you're walking into the clinic because you're not going to keep that in your stomach, right?
- 57:01Wearing comfortable clothes, reducing stressors.
- 57:04But the data shows that the period before the appointment with stress isn't nearly as important
- 57:11as what the stress is afterwards in terms of the ketamine effect.
- 57:15Although we've had many patients report that when they come in in a really foul mood, it really affects how they're experiencing the ketamine.
- 57:22And so they don't want to come in if they've been disturbed, they're not able to let it go as much.
- 57:29There's some people that are actually using oxytocin in their practice to sort of make
- 57:34the feeling within the appointment itself less scary for the patient or nicer.
- 57:40The data doesn't say it has a lot of effect on the efficacy of the ketamine, but it does make the experience for some people better.
- 57:47Some people, it makes it worse.
- 57:48So that's something that can be done.
- 57:51So during this appointment, the set and setting is emphasized.
- 57:55And then what are they gonna do after the session?
- 57:57That they're not gonna drive, they're not gonna be engaged in drinking alcohol, and they're going to avoid stress.
- 58:02And then days following the ketamine treatment, you try to get them to connect with their therapist to recreate the experience and then write down any insights that they have.
- 58:13Dr.
- 58:13Papp has them keep a daily record of their depression.
- 58:17After each session that's encouraged, but many people forget to do that until right before the session with him or with me to fill out this sort of tracking sheet.
- 58:28So we go through this, we talk about it, so it's sort of an education piece of it.
- 58:33And then we go even further and they get this and I won't go through this super carefully, but it's...
- 58:42they have to actually fill it out themselves.
- 58:44So I go through it with them.
- 58:46What are you gonna do the day before?
- 58:47Days before, the day of your ketamine, what are you gonna do afterwards?
- 58:51Because you'd be surprised, you know, no matter how much you educate them, they're gonna come in and do something that is not really helpful.
- 58:58Anyway, so that's how we do good practice to try to follow the patient, you know, from beginning to end.
- 59:05So what is bad practice?
- 59:07Well, it's this ugly slide.
- 59:09It's all sorts of stuff that people do.
- 59:11So there are providers that will treat anybody.
- 59:14You want ketamine?
- 59:15Come on in.
- 59:15They've got hundreds of people.
- 59:17We, of course, are a little biased.
- 59:19We think psychiatrists are the best to administer this, but many people don't believe that.
- 59:25There's no evaluation of what's happening, no measures to say, is this really helping or not helping and treat any sort of condition.
- 59:34They're not adjusting the dose properly or having a consistent dose.
- 59:38You don't medically monitor people.
- 59:40So for example, the oral ketamine, there's often no medical monitoring at all.
- 59:45And you're not really disclosing
- 59:48the potential bad effects of the ketamine.
- 59:51And you don't stop, you just keep going and giving to them as long as people want.
- 59:55Basically these predatory business practices of money over the safety of the patient, more than just the safety, the efficacy.
- 1:00:04During
- 1:00:04COVID, lots of sort of ketamine things popped up and many of them actually ended up going out of business when there was a decrease in the availability of ketamine, but still they
- 1:00:15proliferate and hopefully there will be maybe some standardization of what should happen.
- 1:00:21I think that's what the conferences and the ASKP, American Society of Ketamine
- 1:00:26Providers is trying to address is more of a baseline for how this should be done.
- 1:00:33So I have a couple minutes to just do a couple cases and then we'll have some time for questions.
- 1:00:39I know I went over a lot of this material pretty quickly and I do encourage you to contact us if you have questions.
- 1:00:47So here's the first case:
- 1:00:48So a 42 year old woman with very severe chronic depression all her life, anergic, negative ruminations, low self-esteem and motivation, mild suicidality, increased startle, PTSD,
- 1:01:01insomnia, somatization, rejection sensitivity, and then medical issues of obesity, chronic pain, long history of bad ketamine sessions.
- 1:01:11She had six ketamine-assisted
- 1:01:13sessions and it was just...
- 1:01:15I wouldn't say perfect, but it just went, went very well.
- 1:01:19Her depression scores for BDI went from a 29 to 11 from the initial to the last session.
- 1:01:26In fact, the last session, I wasn't in with her.
- 1:01:29Instead, she recorded on, you know, had a tape recorder.
- 1:01:32She recorded all her own feedback that she wanted for herself.
- 1:01:35So it was a very good outcome.
- 1:01:38But then after that, maybe, I don't know, maybe
- 1:01:41four months later, we get this case.
- 1:01:43And this case looks like the same person, right?
- 1:01:45It's basically the same, you know, female, same age, same symptoms, almost exactly, but it was a disaster.
- 1:01:55It somehow activated in her a dependency, not ketamine dependency, but dependency on her providers.
- 1:02:03She would stay four hours and just ruminate and it was not good.
- 1:02:10She wanted to keep coming, but it didn't seem to be doing any good.
- 1:02:15Her scores weren't improving.
- 1:02:17So we said, you know, we're going to have to terminate the therapy.
- 1:02:21Here again, two cases, extremely different outcome.
- 1:02:24And then the third case is this 53 year old man with this
- 1:02:30terrible, anergic, severe chronic depression since childhood, just has been debilitated.
- 1:02:35In every aspect, he was non-functional, isolated, low motivation.
- 1:02:41He had hypothyroidism, he had a lot of medical issues going along with it.
- 1:02:46So the first thing that happened was that kind of looked at what is his psychiatric history, what are the medications they had been giving him.
- 1:02:53And Dr.
- 1:02:55Papp did psychogenetic testing on him.
- 1:02:58And lo and behold, he was a rapid metabolizer of duloxetine, which was the medication he had been on for years and years and years, 15 milligrams for 15 years, and nobody had ever
- 1:03:09looked at.
- 1:03:10And so he was switched to desvenlafaxine and then added some Buspar and voila, his BDI went from 37 down to 15 within two months.
- 1:03:23So there was weekly psychotherapy.
- 1:03:27It turned out he had pretty severe OCD as well.
- 1:03:28And basically with this patient, you don't need ketamine.
- 1:03:31I mean, sure, you could get it and it might be kind of interesting, but it's not gonna do what it really needs to do.
- 1:03:39So not every patient is gonna need ketamine that comes into your office.
- 1:03:45So the lessons learned from these three cases are,
- 1:03:48that the response to ketamine treatment can be idiosyncratic.
- 1:03:53So, two patients can have very initial presentations the same, but very different outcomes.
- 1:03:59And you never quite know what's going to happen.
- 1:04:01So you cannot promise people anything about ketamine.
- 1:04:06You can say, here's the data, here's what we experience, here's what most people are experiencing, but we can't promise this will be effective for you.
- 1:04:13Some people
- 1:04:13do their six sessions and nothing happens.
- 1:04:16Sometimes people decide to do more than six sessions because they have a little response and then they get a better response.
- 1:04:22But you don't know for sure.
- 1:04:24I would say with suicidality, that's the thing that almost every single time works.
- 1:04:29It's like a miracle drug.
- 1:04:31I've had numerous patients that have been suicidal all their life or very risky suicidal and they get the ketamine treatment and it's gone,
- 1:04:41almost completely gone within the first session.
- 1:04:43So it's being used in some emergency rooms for that as well.
- 1:04:46And then the third case basically illustrated that treatment-resistant depression, which now is really an archaic term for difficult-to-treat depression, may just mean that it's
- 1:04:57been poorly treated depression.
- 1:04:58You haven't really given the medications that they need.
- 1:05:02So you need to stay open to thinking about it differently.
- 1:05:05You don't just...
- 1:05:07you know, book people for ketamine, you try to respond to how the patient is responding to the ketamine or to other medications.
- 1:05:14And just because they're on the ketamine does not mean you stop your traditional antidepressants.
- 1:05:19Antidepressants are meant to be used in conjunction with them.
- 1:05:22Well, I'd like to thank you both for taking your evening to do this.
- 1:05:26Thank you all.
- 1:05:26We really appreciate you and have an absolutely lovely week.